Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/BNC210> ?p ?o }
Showing triples 1 to 64 of
64
with 100 triples per page.
- BNC210 abstract "BNC210 (also known as IW-4123 during its time licensed to Ironwood Pharmaceuticals) is an anxiolytic drug that acts via negative allosteric modulation of the α7-nicotinic acetylcholine receptor, by Bionomics Limited. It demonstrates clinically significant anxiety reduction in both animal models and in Phase I trials.It appears to be devoid of significant sedation or memory-impairing side effects, as well as lacking addictive potential in rat discriminatory models.Phase I trials have shown no serious side effects.Bionomics previously licensed it to Ironwood Pharmaceuticals in January 2012, where it was known as IW-2143. In December 2012, IW-2143 begun undergoing phase I clinical trials in the United States, but in November 2014, was released back to Bionomics in a mutual agreement. Bionomics will now continue development and clinical testing, with Ironwood receiving a royalty for their work done.As of April 2015, BNC210 is in phase II clinical trials.".
- BNC210 atcPrefix "none".
- BNC210 iupacName "(L)-Isoleucyl-(L)-tryptophan".
- BNC210 pubchem "7019084".
- BNC210 thumbnail IW-2143_molecular_structure.png?width=300.
- BNC210 wikiPageID "28376300".
- BNC210 wikiPageLength "4436".
- BNC210 wikiPageOutDegree "18".
- BNC210 wikiPageRevisionID "701587595".
- BNC210 wikiPageWikiLink 5-Hydroxyindoleacetic_acid.
- BNC210 wikiPageWikiLink Addiction.
- BNC210 wikiPageWikiLink Adverse_effect.
- BNC210 wikiPageWikiLink Allosteric_modulator.
- BNC210 wikiPageWikiLink Alpha-7_nicotinic_receptor.
- BNC210 wikiPageWikiLink Amnesia.
- BNC210 wikiPageWikiLink Animal_testing.
- BNC210 wikiPageWikiLink Anxiety.
- BNC210 wikiPageWikiLink Anxiolytic.
- BNC210 wikiPageWikiLink Category:Amino_acids.
- BNC210 wikiPageWikiLink Category:Anxiolytics.
- BNC210 wikiPageWikiLink Category:Nicotinic_antagonists.
- BNC210 wikiPageWikiLink Clinical_trial.
- BNC210 wikiPageWikiLink Ironwood_Pharmaceuticals.
- BNC210 wikiPageWikiLink Kynurenic_acid.
- BNC210 wikiPageWikiLink Phases_of_clinical_research.
- BNC210 wikiPageWikiLinkText "BNC210".
- BNC210 atcPrefix "none".
- BNC210 c "17".
- BNC210 chemspiderid "5382052".
- BNC210 h "23".
- BNC210 inchi "1".
- BNC210 inchikey "BVRPESWOSNFUCJ-LKTVYLICBF".
- BNC210 iupacName "(L)-Isoleucyl-(L)-tryptophan".
- BNC210 legalStatus "Investigational".
- BNC210 n "3".
- BNC210 o "3".
- BNC210 pubchem "7019084".
- BNC210 smiles "CC[C@H][C@@H]N".
- BNC210 stdinchi "1".
- BNC210 stdinchikey "BVRPESWOSNFUCJ-LKTVYLICSA-N".
- BNC210 wikiPageUsesTemplate Template:Anxiolytics.
- BNC210 wikiPageUsesTemplate Template:Cholinergics.
- BNC210 wikiPageUsesTemplate Template:Drugbox.
- BNC210 wikiPageUsesTemplate Template:Nervous-system-drug-stub.
- BNC210 wikiPageUsesTemplate Template:Reflist.
- BNC210 wikiPageUsesTemplate Template:Third-party.
- BNC210 subject Category:Amino_acids.
- BNC210 subject Category:Anxiolytics.
- BNC210 subject Category:Nicotinic_antagonists.
- BNC210 hypernym Drug.
- BNC210 type ChemicalSubstance.
- BNC210 type Drug.
- BNC210 type Drug.
- BNC210 type ChemicalObject.
- BNC210 type Thing.
- BNC210 type Q8386.
- BNC210 comment "BNC210 (also known as IW-4123 during its time licensed to Ironwood Pharmaceuticals) is an anxiolytic drug that acts via negative allosteric modulation of the α7-nicotinic acetylcholine receptor, by Bionomics Limited.".
- BNC210 label "BNC210".
- BNC210 sameAs Q4836115.
- BNC210 sameAs m.0crf3dl.
- BNC210 sameAs Q4836115.
- BNC210 wasDerivedFrom BNC210?oldid=701587595.
- BNC210 depiction IW-2143_molecular_structure.png.
- BNC210 isPrimaryTopicOf BNC210.